Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12714304 | 0.83 | ALDH1A1 (0.41) | SMYD3ALDH1A1TSHRSMN1; SMN2FPR3 | |
| SCHEMBL17682276 | 0.83 | ALDH1A1 (0.41) | SMYD3CCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL2827606 | 0.82 | SMYD3 (0.47) | SMYD3FDPSCCNE1CDK2CDK5 | |
| SCHEMBL14402594 | 0.82 | ALDH1A1 (0.39) | SMYD3ALDH1A1TSHRSMN1; SMN2FPR3 | |
| SCHEMBL1706362 | 0.80 | SMN1; SMN2 (0.39) | CCNE1CDK2CDK5ALDH1A1TSHR | |
| SCHEMBL16267819 | 0.78 | CCNE1 (0.48) | FDPSCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL15296863 | 0.77 | SMYD3 (0.50) | SMYD3FDPSCCNE1CDK2CDK5 | |
| SCHEMBL1398202 | 0.75 | CCNE1 (0.43) | SMYD3FDPSCCNE1CDK2CDK5 | |
| SCHEMBL8751670 | 0.73 | FDPS (0.37) | FDPSCCNE1CDK2CDK5ALDH1A1 | |
| SCHEMBL8833079 | 0.73 | FDPS (0.40) | SMYD3FDPSCCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114121-B1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3114121-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | DGAT2, MGAT2, DGAT1 | SMYD3 1484/4885FDPS 471/4885CCNE1 4690/4885 |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | DGAT2, DGAT1, MGAT2 | SMYD3 1892/4885FDPS 608/4885CCNE1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.